ASCO: Novartis eyes full nod for Gleevec follow-on Scemblix thanks to new leukemia data

Novartis boasts an accelerated approval for its Gleevec follow-on drug Scemblix in previously treated chronic myeloid leukemia. Now with new clinical data, the company hopes to turn it into a full nod.

Scemblix triggered a major molecular response in 37.6% of chronic myeloid leukemia (CML) patients who had tried at least two prior treatments. That was much higher than the 15.8% by Pfizer’s Bosulif.